Protalix BioTherapeutics (PLX) Common Equity (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Common Equity of $67.2 million for Q1 2026, up 48.71% year-over-year from $45.2 million in Q1 2025, and up 39.39% quarter-over-quarter from $48.2 million in Q4 2025.
Protalix BioTherapeutics (PLX) Common Equity (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $67.2 million for Q1 2026.
- In Q1 2026, Common Equity rose 48.71% year-over-year to $67.2 million; the TTM figure through Mar 2026 stood at $67.2 million (up 48.71% YoY), while the FY2025 annual figure was $48.2 million, up 11.62% from the prior year.
- Common Equity for Q1 2026 stood at $67.2 million, up from $48.2 million in the prior quarter.
- The five-year high for Common Equity was $67.2 million in Q1 2026, with the low at -$11.5 million in Q3 2022.
- The 5-year median for Common Equity is $33.6 million (2023), against an average of $27.6 million.
- The sharpest annual moves came in 2022 and 2024: Common Equity slumped 5505.63% in 2022, then jumped 2854.96% in 2024.
- Protalix BioTherapeutics' Common Equity stood at -$10.6 million in 2022, then surged by 415.5% to $33.6 million in 2023, then increased by 28.72% to $43.2 million in 2024, then rose by 11.62% to $48.2 million in 2025, then soared by 39.39% to $67.2 million in 2026.
- Business Quant data shows PLX's Common Equity at $67.2 million in Q1 2026, $48.2 million in Q4 2025, and $52.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 71.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.40 Mn |
| Mar 31, 2026 | 67.23 Mn |
| Dec 31, 2025 | 48.23 Mn |
| Sep 30, 2025 | 52.91 Mn |
| Jun 30, 2025 | 49.90 Mn |
| Mar 31, 2025 | 45.21 Mn |
| Dec 31, 2024 | 43.21 Mn |
| Sep 30, 2024 | 32.44 Mn |
| Jun 30, 2024 | 28.58 Mn |
| Mar 31, 2024 | 29.79 Mn |
| Dec 31, 2023 | 33.57 Mn |
| Sep 30, 2023 | 38.25 Mn |
| Jun 30, 2023 | 39.00 Mn |
| Mar 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | -10.64 Mn |
| Sep 30, 2022 | -11.51 Mn |
| Jun 30, 2022 | -9.89 Mn |
| Mar 31, 2022 | -7.49 Mn |
| Dec 31, 2021 | -6.04 Mn |
| Sep 30, 2021 | 213,000.00 |